In the Claims:

Please amend claims 1, 2, 7, 8, 13, 14, 19, and 20 as follows:

--1. (Three Times Amended) A method of treating urinary incontinence in a human subject suffering from urinary incontinence which comprises administering to the human subject a therapeutically effective amount of a 5-HT_{1F} receptor agonist which selectively activates the human 5-HT_{1F} receptor.--

--2. (Amended) The method of claim 1, wherein the 5-HT_{1F} receptor agonist additionally activates the human 5-HT_{1F} receptor at least ten-fold more than it activates any of the human 5-HT_{1B}, 5-HT_{1E}, 5-HT_{2B}, 5-HT_{5A}, 5-HT_{5B}, or 5-HT_6 receptor.--

--7. (Amended) The method of claim 1, wherein the 5-HT_{1F} receptor agonist activates the human 5-HT_{1F} receptor at least 50-fold more than it activates any of the human 5-HT_{1A}, 5-HT_{1D}, 5-HT_{2A}, 5-HT_{2C}, 5-HT_3, 5-HT_4, or 5-HT_7 receptor.--

--8. (Amended) The method of claim 7, wherein the 5-HT_{1F} receptor agonist additionally activates the human 5-HT_{1F} receptor at least 50-fold more than it activates any of the human 5-HT_{1B}, 5-HT_{1E}, 5-HT_{2B}, 5-HT_{5A}, 5-HT_{5B}, or 5-HT_6 receptor.--

--13. (Amended) The method of claim 7, wherein the 5-HT_{1F} receptor agonist activates the human 5-HT_{1F} receptor at least 100-fold more than it activates any of the human 5-HT_{1A}, 5-HT_{1D}, 5-HT_{2A}, 5-HT_{2C}, 5-HT_3, 5-HT_4, or 5-HT_7

receptor.--

--14. (Amended) The method of claim 13, wherein the 5-HT_{1F} receptor agonist additionally activates the human 5-HT_{1F} receptor at least 100-fold more than it activates any of the human 5-HT_{1B}, 5-HT_{1E}, 5-HT_{2B}, 5-HT_{5A}, 5-HT_{5B}, or 5-HT_6 receptor.--

--19. (Amended) The method of claim 13, wherein the 5-HT_{1F} receptor agonist activates the human 5-HT_{1F} receptor at least 200-fold more than it activates any of the human 5-HT_{1A}, 5-HT_{1D}, 5-HT_{2A}, 5-HT_{2C}, 5-HT_3, 5-HT_4, or 5-HT_7 receptor.--

--20. (Amended) The method of claim 19, wherein the 5-HT_{1F} receptor agonist additionally activates the human 5-HT_{1F} receptor at least 200-fold more than it activates any of the human 5-HT_{1B}, 5-HT_{1E}, 5-HT_{2B}, 5-HT_{5A}, 5-HT_{5B}, or 5-HT_6 receptor.--

Please add new claims 25 and 26:

--25. (New) The method of claim 1, wherein the 5-HT_{1F} receptor agonist selectively activates the human 5-HT_{1F} receptor at least ten-fold more than it activates any of the human 5-HT_{1A}, 5-HT_{1D}, 5-HT_{2A}, 5-HT_{2C}, 5-HT_3, 5-HT_4, or 5-HT_7 receptor.--

--26. (New) The method of claim 1, wherein the 5-HT_{1F} agonist binds to the human 5-HT_{1F} receptor with a Ki value of 7.11 ± 0.76 nM or less.

A marked-up version of the amendments showing the changes made